-
Muscae volitantes: A 19th-century precursor of visual snow syndrome? Cephalalgia (IF 4.9) Pub Date : 2024-03-26 Mark W. Weatherall
PurposeVisual snow syndrome comprises a whole-field static-like visual disturbance, with increased awareness of entopic phenomena, an inability to suppress the ‘just seen’ and photophobia. Visual snow syndrome is often associated with other problems such as headache, tinnitus, and anxiety. The earliest reported case of a patient experiencing symptoms consistent with visual snow syndrome dates only
-
New migraine drugs: A critical appraisal of the reason why the majority of migraine patients do not receive an adequate medication Cephalalgia (IF 4.9) Pub Date : 2024-03-23 Hans Christoph Diener, Arne May
The last three decades have produced several novel and efficient medications to treat migraine attacks and reduce attack frequency. Additionally, promising approaches for the development of acute therapy and migraine prophylaxis continue to be pursued. At the same time as we witness the development of better and more efficient medications with continuously fewer side effects, we also realise that the
-
Melatonin in hemicrania continua and paroxysmal hemicrania Cephalalgia (IF 4.9) Pub Date : 2024-03-22 Sing-ngai Cheung, Renato Oliveira, Peter J Goadsby
BackgroundHemicrania continua (HC) and paroxysmal hemicrania (PH) belong to a group of primary headache disorders called trigeminal autonomic cephalalgias. One of the diagnostic criteria for both HC and PH is the absolute response to the therapeutic dose of indomethacin. However, indomethacin is discontinued in many patients as a result of intolerance to its side effects. Melatonin, a pineal hormone
-
Guidelines of the International Headache Society for controlled trials of pharmacological preventive treatment for persistent post-traumatic headache attributed to mild traumatic brain injury Cephalalgia (IF 4.9) Pub Date : 2024-03-22 Håkan Ashina, Hans-Christoph Diener, Cristina Tassorelli, Ann I. Scher, Richard B. Lipton, Patricia Pozo-Rosich, Alexandra J. Sinclair, Catherine D. Chong, Alan G. Finkel, Messoud Ashina, Todd J. Schwedt, David W. Dodick, Gisela M. Terwindt
BackgroundPersistent headache attributed to traumatic injury to the head is divided into two subtypes, one attributed to moderate or severe traumatic injury and another attributed to mild traumatic injury (i.e., concussion). The latter is much more prevalent, in part because more than 90% of cases with traumatic brain injury are classified as mild. The pathophysiology of persistent post-traumatic headache
-
Breaking barriers in migraine care: Advancing gender medicine to bridge the gap for men Cephalalgia (IF 4.9) Pub Date : 2024-03-19 Simona Sacco, Frank Porreca
-
Investigations of the migraine-provoking effect of levcromakalim in patients with migraine with aura Cephalalgia (IF 4.9) Pub Date : 2024-03-19 Andreas Vinther Thomsen, Mohammad Al-Mahdi Al-Karagholi, Anders Hougaard, Sisse Rye Ostrowski, Ole Birger Pedersen, Thomas Folkmann Hansen, Messoud Ashina
Background/HypothesisExperimental provocation studies have yielded important insights in migraine pathophysiology. Levcromakalim has been previously shown to induce migraine-like attacks with and without aura. In this study, we aim to further explore the migraine aura-inducing potential of levcromakalim.MethodsIn a double-blind, randomized, placebo-controlled cross-over study, 27 adult participants
-
Efficacy and safety of galcanezumab as chronic cluster headache preventive treatment under real world conditions: Observational prospective study Cephalalgia (IF 4.9) Pub Date : 2024-03-19 Raquel Lamas Pérez, Manuel Millán-Vázquez, Carmen González-Oria
BackgroundCalcitonin gene-related peptide has shown to play a central role in cluster headache (CH) pathophysiology. A clinical trial with galcanezumab was carried out in chronic cluster headache (CCH) but did not meet its primay endpoint. However, its off-label use in patients with CCH refractory to other therapies could be considered. We aimed to asses the efficacy and safety of galcanezumab as CCH
-
Evaluation of outcomes of calcitonin gene-related peptide (CGRP)-targeting therapies for acute and preventive migraine treatment based on patient sex Cephalalgia (IF 4.9) Pub Date : 2024-03-13 Frank Porreca, Edita Navratilova, Joe Hirman, Antoinette Maassen van den Brink, Richard B Lipton, David W Dodick
BackgroundWomen show increased prevalence and severity of migraine compared to men. Whether small molecule calcitonin gene-related peptide receptor (CGRP-R) antagonists (i.e., gepants) and monoclonal antibodies targeting either the CGRP-R or the CGRP peptide might show sexually dimorphic outcomes for acute and preventive therapy has not been established.MethodsWe conducted a subpopulation analysis
-
The impact of eating disorders on idiopathic intracranial hypertension Cephalalgia (IF 4.9) Pub Date : 2024-03-09 Therese Wallentin, Jakob Linnet, Mia B Lichtenstein, Nadja S Hansen, Johanne J Korsbæk, Lisbeth Høgedal, Snorre M Hagen, Laleh D Molander, Rigmor H Jensen, Dagmar Beier
BackgroundIdiopathic intracranial hypertension (IIH) occurs more frequently in obese females of childbearing age. A link between eating disorders and poor outcome has been suggested but remains unproven.MethodsThis prospective field study at two tertiary headache centers included patients with clinically suspected IIH after standardized diagnostic work-up. Eating disorders were evaluated using validated
-
Correlation between endometriosis and migraine features: Results from a prospective case-control study Cephalalgia (IF 4.9) Pub Date : 2024-03-04 Aikaterini Selntigia, Caterina Exacoustos, Camille Ortoleva, Consuelo Russo, Giulia Monaco, Francesco Giuseppe Martire, Giuseppe Rizzo, David Della-Morte, Nicola Biagio Mercuri, Maria Albanese
BackgroundEndometriosis and migraine frequently coexist, but only a limited number of studies have focused on their mutual association. The aim of our study was to investigate, in untreated women with comorbid endometriosis/adenomyosis and migraine, the correlation between headache features and endometriotic subtypes and their possible relationship with pain severity and disease disability.MethodsFifty
-
Reduced plasma calcitonin gene-related peptide level identified in cluster headache: A prospective and controlled study Cephalalgia (IF 4.9) Pub Date : 2024-03-04 Anja Sofie Petersen, Nunu Lund, Karl Meßlinger, Sarah Louise Christensen, Mads Barloese, Niklas Rye Jørgensen, Lisette Kogelman, Rigmor Højland Jensen
BackgroundThe role of calcitonin gene-related peptide (CGRP) in the cyclic pattern of cluster headache is unclear. To acquire biological insight and to comprehend why only episodic cluster headache responds to CGRP monoclonal antibodies, we examined whether plasma CGRP changes between disease states (i.e. bout, remission and chronic) and controls.MethodsThe present study is a prospective case–control
-
Increased prevalence of migraine in women with inflammatory bowel disease: A cross-sectional study Cephalalgia (IF 4.9) Pub Date : 2024-03-01 Marta Pascual-Mato, Gabriel Gárate, Carlota de Prado-Tejerina, María José García, Beatriz Castro, Vicente González-Quintanilla, Jorge Madera, Javier Crespo, Julio Pascual, Monserrat Rivero
BackgroundSome studies have suggested an association between migraine and inflammatory bowel disease. We determined migraine prevalence in a cohort of patients with inflammatory bowel disease.MethodsPatients with inflammatory bowel disease aged 18–65 years were interviewed using an ad hoc headache questionnaire. Those who admitted a history of headache in the last year answered the three questions
-
-
SUNCT, SUNA and short-lasting unilateral neuralgiform headache attacks: Debates and an update Cephalalgia (IF 4.9) Pub Date : 2024-02-28 Mi-Kyoung Kang, Soo-Jin Cho
BackgroundShort-lasting unilateral neuralgiform headache attacks (SUNHA) have the features of both short-lasting unilateral neuralgiform pain, such as trigeminal neuralgia or stabbing headache, and associated trigeminal autonomic symptoms, such as paroxysmal hemicrania or cluster headache. Recognizing and adequately treating SUNHA is essential but current treatment methods are ineffective in treating
-
Quantifying sensory thresholds along the migraine cycle: An exploratory longitudinal study Cephalalgia (IF 4.9) Pub Date : 2024-02-28 Nara Ikumi, Angela Marti-Marca, Anna de la Torre-Suñe, Xim Cerda-Company, Adrià Vilà-Balló, Victor J Gallardo, Edoardo Caronna, Alicia Alpuente, Patricia Pozo-Rosich
BackgroundTo date, a number of studies on migraine have cross-sectionally evaluated sensory sensitivity with aversion thresholds/scores along the migraine cycle, reporting a decreased tolerance to sensory stimuli in different sensory modalities. Our hypothesis was that patients with migraine would exhibit heightened sensitivity to sound, light, touch and smell on days where they reported greater headache
-
Pathophysiology of cluster headache: From the trigeminovascular system to the cerebral networks Cephalalgia (IF 4.9) Pub Date : 2024-02-28 Gianluca Coppola, Chiara Abagnale, Gabriele Sebastianelli, Peter J. Goadsby
BackgroundDespite advances in neuroimaging and electrophysiology, cluster headache’s pathogenesis remains unclear. This review will examine clinical neurophysiology studies, including electrophysiological and functional neuroimaging, to determine if they might help us construct a neurophysiological model of cluster headache.ResultsClinical, biochemical, and electrophysiological research have implicated
-
Comparative efficacy, quality of life, safety, and tolerability of atogepant and rimegepant in migraine prevention: A matching-adjusted indirect comparison analysis Cephalalgia (IF 4.9) Pub Date : 2024-02-27 Cristina Tassorelli, Kateryna Onishchenko, Rashmi B. Halker Singh, Molly Duan, Laure Dupont-Benjamin, Matthew Hemstock, Corey Voller, Peter McAllister, Stephanie J. Nahas, Pranav Gandhi, Jessica Ailani
BackgroundComparative evaluations of preventive migraine treatments can help inform clinical decision making for managing migraine in clinical practice.MethodsAn anchored matching-adjusted indirect comparison analysis was conducted using pooled participant-level data from two phase 3 atogepant trials (ADVANCE and PROGRESS) and one phase 2/3 rimegepant trial (BHV3000-305) to evaluate the relative efficacy
-
Health care resource utilization and costs associated with diagnosed medication overuse headache and potential acute medication overuse in individuals with migraine Cephalalgia (IF 4.9) Pub Date : 2024-02-27 Anand R. Shewale, Jennifer A. Brandenburg, Kate Burslem, Richard B. Lipton, Jalpa A. Doshi
ObjectiveEstimate health care resource utilization and costs associated with medication overuse headache and potential acute medication overuse.MethodsA retrospective analysis was conducted with Clinformatics Data Mart data (1 January 2019–31 December 2019) that included continuously enrolled commercially insured adults with migraine (International Classification of Diseases, Tenth Revision, Clinical
-
Bioequivalence of rimegepant, a small molecule CGRP receptor antagonist, administered as an oral tablet, a sublingual orally disintegrating tablet, and a supralingual orally disintegrating tablet: two phase 1 randomized studies in healthy adults Cephalalgia (IF 4.9) Pub Date : 2024-02-17 Robert Croop, Rajinder Bhardwaj, Matt S. Anderson, Kyle T. Matschke, Jennifer Hould, Richard Bertz, Jing Liu, Richard B. Lipton
BackgroundRimegepant is an orally administered small molecule calcitonin gene-related peptide receptor antagonist indicated for the acute and preventive treatment of migraine.MethodsTwo single-center, phase 1, open-label, randomized bioequivalence studies were conducted in healthy adult non-smokers, aged 18–55 years. One study compared the rate and extent of absorption of the marketed formulation of
-
Vagus nerve stimulation inhibits cortical spreading depression via glutamate-dependent TrkB activation mechanism in the nucleus tractus solitarius Cephalalgia (IF 4.9) Pub Date : 2024-02-08 Tzu-Ting Liu, Shih-Pin Chen, Shuu-Jiun Wang, Jiin-Cherng Yen
BackgroundVagus nerve stimulation (VNS) was recently found to inhibit cortical spreading depression (CSD), the underlying mechanism of migraine aura, through activation of the nucleus tractus solitarius (NTS), locus coeruleus (LC) and dorsal raphe nucleus (DRN). The molecular mechanisms underlying the effect of VNS on CSD in these nuclei remain to be explored. We hypothesized that VNS may activate
-
Long-term clinical and ultrasound follow-up after transient perivascular inflammation of the carotid artery (TIPIC) syndrome: a multicenter study Cephalalgia (IF 4.9) Pub Date : 2024-02-06 Michael Obadia, Nathalie Nasr, Geoffroy Volle, Frédérique Charbonneau, Jessica Guillaume, Olivier Naggara, Jean Claude Sadik, Augustin Lecler
BackgroundThe present study aimed to describe the clinical and ultrasound (US) long-term follow-up of patients with transient perivascular inflammation of the carotid artery (TIPIC) syndrome and the risk of recurrence.MethodsWe enrolled patients with a definitive diagnosis of TIPIC syndrome who were included in a retrospective multicenter study. These patients were recontacted at least six months after
-
How migraine and its associated treatment impact on pregnancy outcomes: Umbrella review with updated systematic review and meta-analysis Cephalalgia (IF 4.9) Pub Date : 2024-02-06 Katherine Phillips, Conor Clerkin-Oliver, Krishnarajah Nirantharakumar, Francesca L Crowe, Benjamin R Wakerley
BackgroundMigraine is common in reproductive aged women. Understanding the impact of migraine and associated treatments on pregnancy outcomes remains very important. An umbrella review of systematic reviews, with or without meta-analyses, examined the link between migraine and pregnancy outcomes.MethodsWe systematically searched Medline, Embase and Cochrane to 27 October 2022. Quality appraisal was
-
Premonitory symptoms in migraine: A REFORM Study Cephalalgia (IF 4.9) Pub Date : 2024-02-01 Janu Thuraiaiyah, Håkan Ashina, Rune H Christensen, Haidar M Al-Khazali, Astrid Wiggers, Faisal Mohammad Amin, Timothy J Steiner, Messoud Ashina
BackgroundEstimates of proportions of people with migraine who report premonitory symptoms vary greatly among previous studies. Our aims were to establish the proportion of patients reporting premonitory symptoms and its dependency on the enquiry method. Additionally, we investigated the impact of premonitory symptoms on disease burden using Headache Impact Test (HIT-6), Migraine Disability Assessment
-
The long-term effect of work schedule, shift work disorder, insomnia and restless legs syndrome on headache among nurses: A prospective longitudinal cohort study Cephalalgia (IF 4.9) Pub Date : 2024-01-12 Espen Saxhaug Kristoffersen, Ståle Pallesen, Siri Waage, Bjørn Bjorvatn
BackgroundThe preset study aimed to explore whether work schedules and sleep disorders predict the onset of headache.MethodsA longitudinal study was conducted with questionnaire data from 2014 (baseline) and 2017 (follow-up) on work schedule, number of night shifts, number of quick returns, insomnia, shift work disorder (SWD), restless legs syndrome (RLS) and validated headache diagnoses among 1560
-
Childhood primary stabbing headache: A double center study Cephalalgia (IF 4.9) Pub Date : 2024-01-12 Gabriele Monte, Laura Papetti, Fabiana Ursitti, Giorgia Sforza, Samuela Tarantino, Martina Checchi Proietti, Daniela D'Agnano, Vittorio Sciruicchio, Massimiliano Valeriani
BackgroundPrimary stabbing headache (PSH) is an idiopathic headache disorder characterized by head pain occurring as a transient and localized single stab or a series of stabs. The present study aimed to examine the characteristics of childhood PSH and whether they fit the International Classification of Headache Disorders, 3rd edition (ICHD-3) criteria. We also investigated the association with migraine
-
Pharmacologic characterization of atogepant: A potent and selective calcitonin gene–related peptide receptor antagonist Cephalalgia (IF 4.9) Pub Date : 2024-01-12 Eric Moore, Ian M Bell, Mark E Fraley, Christopher S Burgey, Rebecca B White, Chi-Chung Li, Christopher P Regan, Andrew Danziger, Steve P McGaraughty, Ghazal Naseri Kouzehgarani, Christopher Salvatore, Pradeep Banerjee
BackgroundThe trigeminal sensory neuropeptide calcitonin gene–related peptide (CGRP) is identified as an essential element in migraine pathogenesis.MethodsIn vitro and in vivo studies evaluated pharmacologic properties of the CGRP receptor antagonist atogepant. Radioligand binding using 125I-CGRP and cyclic adenosine monophosphate (cAMP) accumulation assays were conducted in human embryonic kidney
-
Calcitonin gene-related peptide receptor antagonism reduces motion sickness indicators in mouse migraine models Cephalalgia (IF 4.9) Pub Date : 2024-01-12 Shafaqat M Rahman, Anne E Luebke
BackgroundMigraine and vestibular migraine are disorders associated with a heightened motion sensitivity that provoke symptoms of motion-induced nausea and motion sickness. VM affects ∼3% of adults in the USA and affects three-fold more women than men. Triptans (selective serotonin receptor agonists) relieve migraine pain but lack efficacy for vertigo. Murine models of photophobia and allodynia have
-
The midfacial segment pain: little known disorder in need of scientific evaluation Cephalalgia (IF 4.9) Pub Date : 2024-01-12 Marcin Straburzyński, Adrian M. Agius, Magdalena Boczarska-Jedynak, Eliza Brożek-Mądry, Karolina Dżaman, Elżbieta Gradek-Kwinta, Anna Gryglas-Dworak, Magdalena Nowaczewska, Anshul Sama, Joanna Smardz, Hoo Kee Tsang, Mieszko Więckiewicz, Marta Waliszewska-Prosół
Despite its inclusion in the International Classification of Orofacial Pain, tension-type orofacial pain has little support in the scientific literature. However, a similar-in-phenotype orofacial pain perceived in the middle segment of the face has been described by few case series from mostly ear, nose and throat clinics. The authors of these descriptions used the term ‘midfacial segment pain’. Patients
-
No wearing-off effect of erenumab or fremanezumab for chronic migraine prevention: a single-center, real-world, observational study Cephalalgia (IF 4.9) Pub Date : 2024-01-12 Anna Maria Florescu, Lærke Vig Lannov, Samaira Younis, Christopher Kjaer Cullum, Basit Ali Chaudhry, Thien Phu Do, Faisal Mohammad Amin
BackgroundThe present study investigates the wearing-off effect in adults with chronic migraine treated with erenumab or fremanezumab.MethodsThis real-world observational study was based on pre-collected headache diaries from chronic migraine patients in treatment with either monthly injections of 140 mg of erenumab or 225 mg of fremanezumab. Consistent wearing-off was defined as an increase of ≥2
-
Cumulative exposure to estrogen may increase the risk of migraine in women Cephalalgia (IF 4.9) Pub Date : 2024-01-12 Nora Stensland Bugge, Kjersti Grøtta Vetvik, Karl Bjørnar Alstadhaug, Tonje Braaten
BackgroundMigraine is a common disorder, particularly affecting women during their reproductive years. This female preponderance has been linked to exposure to female sex hormones.MethodsWe used self-reported data from women born in 1943–1965 enrolled in the Norwegian Women and Cancer Study to examine the differences between women with migraine and women without migraine in a prospective design with
-
Treatment patterns and characteristics of headache in patients in Japan: A retrospective cross-sectional and longitudinal analysis of health insurance claims data Cephalalgia (IF 4.9) Pub Date : 2024-01-09 Masahito Katsuki, Yasuhiko Matsumori, Taisuke Ichihara, Yuya Yamada, Shin Kawamura, Kenta Kashiwagi, Akihito Koh, Tetsuya Goto, Kazuma Kaneko, Naomichi Wada, Fuminori Yamagishi
BackgroundThe present study aimed to investigate prescription patterns for patients aged over 17 years with headaches in the REZULT database.MethodsWe conducted a cross-sectional study (Study 1) of the proportion of over-prescription of acute medications (≥30 tablets/90 days for triptans, combination non-steroidal anti-inflammatory drugs (NSAIDs) and multiple types; ≥45 tablets/90 days for single NSAIDs)
-
Activation of ATP-sensitive potassium channels triggers migraine attacks independent of calcitonin gene-related peptide receptors: a randomized placebo-controlled trial Cephalalgia (IF 4.9) Pub Date : 2024-01-05 Bianca Raffaelli, Thien Phu Do, Basit Ali Chaudhry, Faisal Mohammad Amin, Håkan Ashina, Josefin Snellman, Tina Maio-Twofoot, Messoud Ashina
BackgroundThe present study aimed to investigate whether levcromakalim, a KATP channel opener, induces migraine attacks in people with migraine pre-treated with erenumab, a monoclonal CGRP receptor antibody.MethodsIn this double-blind, placebo-controlled, two-way cross-over study, adults with migraine without aura received a subcutaneous injection of 140 mg of erenumab on day 1. Subsequently, they
-
Grey matter structure within the visual networks in migraine with aura: multivariate and univariate analyses Cephalalgia (IF 4.9) Pub Date : 2024-01-03 David M. Niddam, Kuan-Lin Lai, Yi-Ting Hsiao, Yen-Feng Wang, Shuu-Jiun Wang
BackgroundThe visual cortex is involved in the generation of migraine aura. Voxel-based multivariate analyses applied to this region may provide complementary information about aura mechanisms relative to the commonly used mass-univariate analyses.MethodsStructural images constrained within the functional resting-state visual networks were obtained in migraine patients with (n = 50) and without (n
-
Systemic allergic reaction to galcanezumab (emgality): a case report Cephalalgia (IF 4.9) Pub Date : 2024-01-03 Michael J. Pico, Malaka Badri, Nathan Michalak, Jason W. Siefferman
BackgroundA previously unreported systemic reaction to Galcanezumab (Emgality) is described. Galcanezumab is a humanized monoclonal antibody designed to bind to calcitonin gene-related peptide, a neuropeptide associated with neurogenic inflammation during migraine attacks. Although clinical trials showed that Galcanezumab had few adverse reactions (injection site related erythema, pruritus, and swelling)
-
The International Classification of Headache Disorders: History and future perspectives Cephalalgia (IF 4.9) Pub Date : 2024-01-02 Jes Olesen
PurposeThe International Classification of Headache Disorders (ICHD) is universally accepted and forms the basis of headache management and clinical, experimental and pharmacological headache research. The present review summarizes the history of the three different editions of the classification, concentrating on aspects of general interest that are still valid today.MethodsThe article is based on
-
Identification of brain areas in mice with peak neural activity across the acute and persistent phases of post-traumatic headache. Cephalalgia (IF 4.9) Pub Date : 2023-11-01 Megan Rudolph,Caroline Kopruszinski,Chen Wu,Edita Navratilova,Todd J Schwedt,David W Dodick,Frank Porreca,Trent Anderson
BACKGROUND Post-traumatic headache is very common after a mild traumatic brain injury. Post-traumatic headache may persist for months to years after an injury in a substantial proportion of people. The pathophysiology underlying post-traumatic headache remains unknown but is likely distinct from other headache disorders. Identification of brain areas activated in acute and persistent phases of post-traumatic
-
Real-world effectiveness of fremanezumab for the preventive treatment of migraine: Interim analysis of the pan-European, prospective, observational, phase 4 PEARL study. Cephalalgia (IF 4.9) Pub Date : 2023-11-01 Messoud Ashina,Dimos D Mitsikostas,Faisal Mohammad Amin,Pinar Kokturk,Christoph J Schankin,Gurdal Sahin,Patricia Pozo-Rosich,Paul J Dorman,Tomáš Nežádal,Anne Christine Poole,Isabel Pavão Martins,Marja-Liisa Sumelahti,Verena Ramirez Campos,Andrew H Ahn,Leonidas Lyras,Cristina Tassorelli
BACKGROUND The ongoing Pan-European Real Life (PEARL) phase 4 study is evaluating fremanezumab effectiveness and safety for the prevention of episodic and chronic migraine. This interim analysis reports primary, secondary and exploratory endpoints from when 500 participants completed at least six months of treatment. METHODS Adults with episodic migraine or chronic migraine maintaining daily headache
-
InfluenCEF study: Clinical phenotype and duration of headache attributed to influenza infection. Cephalalgia (IF 4.9) Pub Date : 2023-11-01 David García-Azorín,Laura Santana-López,José Eugenio Lozano-Alonso,Ana Ordax-Díez,Yésica González-Osorio,Silvia Rojo-Rello,José M Eiros,Javier Sánchez-Martínez,Andrea Recio-García,Álvaro Sierra-Mencía,Ivan Sanz-Muñoz,Ángel Luis Guerrero-Peral
INTRODUCTION Headache is a frequent symptom of infections. We aimed to characterize the clinical phenotype and duration of headache attributed to influenza infection. METHODS Prospective cohort study done in 53 primary care centers between January and April 2023. Patients were included if they had a confirmed influenza diagnosis, were older than 15 years and had a new-onset headache. Patients' demographics
-
Paroxysmal hemicrania and hemicrania continua: Review on pathophysiology, clinical features and treatment. Cephalalgia (IF 4.9) Pub Date : 2023-11-01 Anish Bahra
Paroxysmal hemicrania and hemicrania continua are indometacin-sensitive trigeminal autonomic cephalalgias, a terminology which reflects the predominant distribution of the pain, observable cranial autonomic features and shared pathophysiology. Understanding the latter is limited, both by low prevalence and the intricacies of studying brain function, requiring multimodal techniques to glean insights
-
Lack of reproducibility of resting-state functional MRI findings in migraine with aura. Cephalalgia (IF 4.9) Pub Date : 2023-11-01 Anders Hougaard,David Gaist,Ellen Garde,Pernille Iversen,Camilla G Madsen,Kirsten O Kyvik,Messoud Ashina,Hartwig R Siebner,Kristoffer H Madsen
BACKGROUND Several studies have applied resting-state functional MRI to examine whether functional brain connectivity is altered in migraine with aura patients. These studies had multiple limitations, including small sample sizes, and reported conflicting results. Here, we performed a large, cross-sectional brain imaging study to reproduce previous findings. METHODS We recruited women aged 30-60 years
-
Evaluation of the ICHD-3 diagnostic criteria for cardiac cephalalgia and new proposal. Cephalalgia (IF 4.9) Pub Date : 2023-11-01 María Pilar Navarro-Pérez,Sonia Santos-Lasaosa,Jes Olesen
BACKGROUND The current International Classification of Headache Disorders, 3rd edition (ICHD-3) diagnostic criteria for cardiac cephalalgia were established according to previous case reports and the opinion of experts. We aimed to assess the ICHD-3 diagnostic criteria for cardiac cephalalgia. METHODS We conducted a series of cases study and evaluated these criteria in 54 patients with cardiac cephalalgia
-
Response to Letter to the Editor, Comment on "Effect of COVID vaccinations on monthly migraine days". Cephalalgia (IF 4.9) Pub Date : 2023-11-01 Britt van der Arend,Gisela M Terwindt,
-
Hypersensitivity to opening of ATP-sensitive potassium channels in post-traumatic headache. Cephalalgia (IF 4.9) Pub Date : 2023-11-01 Haidar M Al-Khazali,Rune H Christensen,David W Dodick,Basit Ali Chaudhry,Rami Burstein,Håkan Ashina
OBJECTIVE To investigate whether levcromakalim (a KATP channel opener) induces migraine-like headache in people with persistent post-traumatic headache who had no known history of migraine. METHODS In a randomized, double-blind, placebo-controlled, 2-way crossover trial, participants were randomly assigned to receive a 20-minute continuous intravenous infusion of levcromakalim (50 µg/mL) or placebo
-
Comment on "Effect of COVID vaccination on monthly migraine days". Cephalalgia (IF 4.9) Pub Date : 2023-11-01 Hinpetch Daungsupawong,Viroj Wiwanitkit
-
Editorial: A neglected group of headache disorders. Cephalalgia (IF 4.9) Pub Date : 2023-11-01 Stefan Evers,Roberto De Icco
-
Body mass index and migraine in adolescence: A nationwide study. Cephalalgia (IF 4.9) Pub Date : 2023-10-01 Yair Zloof,Avishai M Tsur,Maya Simchoni,Estela Derazne,Dorit Tzur,Asaf Honig,Maya Braun,Esther Ganelin-Cohen,Gil Amarilyo,Orit Pinhas-Hamiel,Arnon Afek,Gilad Twig
BACKGROUND The association between body mass index (BMI) and migraine in adults has been well established. However, studies in children and adolescents are inconclusive. We aimed to study the association between BMI and migraine using a national dataset that comprises the electronic medical records of more than two million adolescents. METHODS This study included all Israeli adolescents (57.7% males
-
Cigarette smoking history (personal and secondary childhood exposure) in non-cluster headache trigeminal autonomic cephalalgias: A clinic based study. Cephalalgia (IF 4.9) Pub Date : 2023-10-01 Todd D Rozen
OBJECTIVE To look at cigarette smoking history (personal and secondary exposure as a child) in non-cluster headache trigeminal autonomic cephalalgias seen at a headache clinic and to determine smoking exposure prevalence utilizing previously published data. METHODS Retrospective chart review and PubMed/Google Scholar search. RESULTS Forty-eight clinic patients met ICHD-3 criteria for non-cluster headache
-
Efficacy and safety of monoclonal antibodies targeting CGRP in migraine prevention. GRADE tables elaborated by the ad hoc working group of the International Headache Society. Cephalalgia (IF 4.9) Pub Date : 2023-10-01 Katina Aleksovska,Andrew D Hershey,Marie Deen,Robert de Icco,Mi Ji Lee,Hans-Christoph Diener
OBJECTIVES Grading of Recommendations, Assessment Development and Evaluation (GRADE) tables were created using a standardized and independent assessment of the efficacy and side effects of treatments with monoclonal antibodies (mAb) against calcitonin gene-related peptide (CGRP) or the CGRP receptor for the prevention of migraine. We hope to provide support for author groups writing national or regional
-
Abnormal heart rate variability and its application in predicting treatment efficacy in patients with chronic migraine: An exploratory study. Cephalalgia (IF 4.9) Pub Date : 2023-10-01 Chun-Hsiang Chuang,Jhe-Yu Li,Jung-Tai King,Wei-Ta Chen,Shih-Pin Chen,Yen-Feng Wang,Hung-Yu Liu,Fu-Jung Hsiao,Li-Ling Hope Pan,Shuu-Jiun Wang,Kuan-Lin Lai
AIM This study aimed to investigate the extent of autonomic nervous system dysfunction in patients with chronic migraine using heart rate variability analysis. In addition, we explored the potential association between heart rate variability and treatment outcomes in patients receiving preventive treatment. METHODS In this cross-sectional and prospective study, we compared heart rate variability profiles
-
The genetics and chronobiology of cluster headache. Cephalalgia (IF 4.9) Pub Date : 2023-10-01 Andrea Carmine Belin,Mads Christian Barloese
BACKGROUND/HYPOTHESIS Cluster headache displays uniquely rhythmic patterns in its attack manifestation. This strong chronobiological influence suggests that part of the pathophysiology of cluster headache is distinctly different from migraine and has prompted genetic investigations probing these systems. METHODS This is a narrative overview of the cluster headache chronobiological phenotype from the
-
Prolonged headache with vaccine- and dose-specific headache pattern associated with vaccine against SARS-CoV-2 in patients with migraine. Cephalalgia (IF 4.9) Pub Date : 2023-10-01 Ai Seon Kuan,Shih-Pin Chen,Yen-Feng Wang,Shuu-Jiun Wang
OBJECTIVE To examine SARS-CoV-2 vaccine-related headache characteristics and risk factors in migraine patients. METHODS This retrospective cohort study included 732 migraine patients who had AstraZeneca Vaxzevria, Pfizer-BioNTech Comirnaty, or Moderna Spikevax vaccines. Participants provided information through questionnaires and headache diaries. Headache frequency before and after vaccination and
-
What proportion of people with migraine report postdromal symptoms? A systematic review and meta-analysis of observational studies. Cephalalgia (IF 4.9) Pub Date : 2023-10-01 Rune Häckert Christensen,Anna Kristina Eigenbrodt,Håkan Ashina,Timothy J Steiner,Messoud Ashina
BACKGROUND Postdromal symptoms, following headache resolution, are said to constitute a distinct phase of the migraine attack. We question the evidence for this, with regard both to the nature of such symptoms and to how often they are reported to occur. METHODS We searched the Pubmed and Embase databases for relevant articles from their inception until 25 May 2023. We included observational studies
-
An exploratory analysis of clinical and sociodemographic factors in CGRP-induced migraine attacks: A REFORM study. Cephalalgia (IF 4.9) Pub Date : 2023-10-01 Haidar M Al-Khazali,Håkan Ashina,Rune Häckert Christensen,Astrid Wiggers,Kathrine Rose,Afrim Iljazi,Henrik W Schytz,Faisal Mohammad Amin,Messoud Ashina
OBJECTIVE To investigate whether clinical and sociodemographic factors are associated with calcitonin gene-related peptide (CGRP) induced migraine attacks. METHODS A total of 139 participants with migraine received a 20-minute intravenous infusion of CGRP (1.5 µg/min) on a single experiment day. The incidence of CGRP-induced migraine attacks was recorded using a headache diary during the 12-hour observational
-
The effect of low dose thyroid replacement therapy in patients with episodic migraine and subclinical hypothyroidism: A randomised placebo-controlled trial. Cephalalgia (IF 4.9) Pub Date : 2023-10-01 Priya Dev,T T Favas,Rishab Jaiswal,Mareena Cyriac,Vijaya Nath Mishra,Abhishek Pathak
INTRODUCTION Migraine is a common headache syndrome associated with various other comorbidities. Thyroid replacement in migraine patients with hypothyroidism improves headaches; however, thyroid hormone replacement in subclinical hypothyroidism is debatable, and its efficacy is not known. OBJECTIVE AND METHODOLOGY This prospective, single-centre, quasi-randomised interventional study was conducted
-
Central sensitization mechanisms in chronic migraine with medication overuse headache: a study of thalamocortical activation and lateral cortical inhibition. Cephalalgia (IF 4.9) Pub Date : 2023-10-01 Gabriele Sebastianelli,Francesco Casillo,Chiara Abagnale,Antonio Di Renzo,Ettore Cioffi,Vincenzo Parisi,Cherubino Di Lorenzo,Federica Fazio,Fausto Petricola,Consalvo Mattia,Mariano Serrao,Jean Schoenen,Gianluca Coppola
BACKGROUND It is unclear whether cortical hyperexcitability in chronic migraine with medication overuse headache (CM-MOH) is due to increased thalamocortical drive or aberrant cortical inhibitory mechanisms. METHODS Somatosensory evoked potentials (SSEP) were performed by electrical stimulation of the median nerve (M), ulnar nerve (U) and simultaneous stimulation of both nerves (MU) in 27 patients
-
Epidemiology, burden and clinical spectrum of cluster headache: a global update. Cephalalgia (IF 4.9) Pub Date : 2023-09-01 Seung Ae Kim,So Youn Choi,Michelle Sojung Youn,Patricia Pozo-Rosich,Mi Ji Lee
BACKGROUND This narrative review aims to broaden our understanding of the epidemiology, burden and clinical spectrum of cluster headache based on updated findings with a global perspective. METHODS We conducted a literature search on the following topics: (a) epidemiology; (b) burden: quality of life, disability, economic burden, job-related burden and suicidality; and (c) clinical spectrum: male predominance
-
Long-term outcomes of nummular headache: A series of 168 patients and 1198 patient-years of follow-up. Cephalalgia (IF 4.9) Pub Date : 2023-09-01 Cristina García-Iglesias,Ana González-Celestino,Álvaro Sierra Mencía,Yésica González Osorio,Andrea Recio García,Cristina Martínez-Badillo,Ana Echavarría Íñiguez,Berta Varona-Galán,David García-Azorín,Ángel Luis Guerrero-Peral
BACKGROUND Since the first description of nummular headache (NH), more than 500 cases have been described, delineating its clinical phenotype and response to treatment. However, data on the natural history of NH and outcomes during long-term follow-up are not currently available. The present study aimed to describe the long-term outcomes and follow-up of a large series of patients with NH. METHODS
-
Effect of COVID vaccination on monthly migraine days: a longitudinal cohort study. Cephalalgia (IF 4.9) Pub Date : 2023-09-01 Britt W H van der Arend,Mirthe M Bloemhof,Alle G van der Schoor,Erik W van Zwet,Gisela M Terwindt
BACKGROUND This longitudinal cohort study aimed to investigate changes in migraine-related outcomes following COVID-19 infection and vaccination. METHODS We identified 547 clinically diagnosed migraine patients from the Leiden Headache Center who kept a headache E-diary during the COVID-19 pandemic (February 2020 to August 2022). We sent a questionnaire to register their COVID-19 infection and/or vaccination
-
Guidelines of the International Headache Society for Controlled Clinical Trials in Idiopathic Intracranial Hypertension. Cephalalgia (IF 4.9) Pub Date : 2023-08-01 Susan P Mollan,Clare L Fraser,Kathleen B Digre,Hans-Christoph Diener,Richard B Lipton,Marianne Juhler,Neil R Miller,Patricia Pozo-Rosich,Mansoureh Togha,Kristian Brock,Marc J Dinkin,Carmen K M Chan,Cristina Tassorelli,Alex J Sinclair,Gisela M Terwindt,Rigmor H Jensen
The quality of clinical trials is essential to advance treatment, inform regulatory decisions and meta-analysis. With the increased incidence of idiopathic intracranial hypertension and the emergence of clinical trials for novel therapies in this condition, the International Headache Society Guidelines for Controlled Clinical Trials in Idiopathic Intracranial Hypertension aims to establish guidelines
-
Recovery and long-term outcome after neurosurgical closure of spinal CSF leaks in patients with spontaneous intracranial hypotension. Cephalalgia (IF 4.9) Pub Date : 2023-08-01 Florian Volz,Christian Fung,Katharina Wolf,Niklas Lützen,Horst Urbach,Luisa Mona Kraus,Mazin Omer,Jürgen Beck,Amir El Rahal
INTRODUCTION Spontaneous intracranial hypotension due to a spinal cerebrospinal fluid leak causes orthostatic headaches and impacts quality of life. Successful closure rates are often reported, whereas data on long-term outcome are still scarce. METHODS Between April 2020 and December 2022 surgically treated patients completed the Headache Impact Test-6 prior to surgery and at 14 days, three months